Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee

Randomized Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee: Augmented Microfracture Technique vs. 3rd Generation of ACI

The major objective of this study is to evaluate the efficacy of the MACT versus the AMT for the treatment of large cartilage defects in patellofemoral and femorotibial injuries.

Study Overview

• Status: Not yet recruiting
• Conditions: Chondral Defect; Articular Cartilage Defect; Osteochondritis
• Intervention / Treatment: Procedure: MACT; Procedure: AMT

Detailed Description

Knee cartilage injuries are common, especially in young active adults, and have the potential to progress to osteoarthritis if left untreated, which would disable a large part of the population with joint functionality loss.The issue with knee cartilage remains in the fact that the tissue has very limited healing potential as it contains no blood vessels allowing a supply in cells for a proper regeneration. Many surgical techniques have been developed for cartilage repair, however, traditional methods have shown their limitations, especially in the case of large defects. More importantly, there is no consensus on novel surgical techniques. Therefore, the choice of a proper cartilage treatment becomes crucial Worldwide, because the aging population is increasing rapidly and there is a need to remain functional and independent as long as possible.

The overall objective of the present study is to compare two advanced surgical techniques for the treatment of large defects in cartilage: one technique consists of a more conventional and widely used approach, which stimulates the natural repair of the tissue by making micro-holes in the bone, allowing the recruitment cells from the underneath bone marrow and stabilize them with a membrane to repair the defect (technique called enhanced microfracture or AMT); and the other technique called MACT, consists of taking patients own cartilage cells from a small biopsy and growing them on a membrane to form a cartilage tissue in vitro, which is then implanted surgically at the location of the injury. This second technique has the advantage of cellular assistance in the surgery enabling to improve the regeneration.

The purpose of this study is to determine which technique (AMT or MACT) is the most appropriate to treat large cartilage injuries, in order to propose the best therapeutic option depending on the severity, size and location of the injury in the joint to the patient.

• Study Type: Interventional
• Enrollment (Estimated): 80
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Robin MARTIN, MD; Phone Number: 41 021 314 76 79; Email: robin.martin@chuv.ch
• Study Contact Backup: Name: Virginie PHILIPPE, Ph-D; Phone Number: 41 021 314 90 18; Email: virginie.philippe@chuv.ch

Study Locations

• Switzerland
  • Canton of Fribourg
    • Fribourg, Canton of Fribourg, Switzerland, 1708
      • Hôpital Fribourgeois- HFR
      • Contact: Daniel PETEK, MD; Phone Number: 41 78 709 86 04; Email: daniel.petek@h-fr.ch
  • Canton of Vaud
    • Lausanne, Canton of Vaud, Switzerland, 1011
      • Centre Hospitalier Universitaire Vaudois - CHUV
      • Contact: Robin MARTIN, MD; Phone Number: 41 021 314 76 79; Email: robin.martin@chuv.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years to 50 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients aged between 15-50 years
• Symptomatic chondral and osteochondral defect, grade III and IV according to the ICRS classification, and size between 2.5 and 15 cm2
• Failure of a conservative treatment
• Patient in good general condition, documented by an ASA score ≤ 2 (American Society of Anesthesiologists)
• Patient considered compliant and able to participate in rehabilitation and pre- and post-operative follow-up
• Consent to participate in the study

Exclusion Criteria:

• All inflammatory and synovial pathologies
• Diffuse or mirror lesions
• An unfavorable biomechanical environment
• Obesity grade II or higher, with a BMI>35 kg/m2
• Active smoking/ active drug dependency (hard drugs)
• Poor compliance
• The patient is already part of another clinical trial that may compromise the present study
• Vulnerable populations (except minors aged 15-18 years)
• Presence of open growth plate (15-18 years)
• Pregnancy or planned pregnancy during the study (MRI-related contra-indication)
• Proven allergy to penicillin and gentamicin (for MACT group) and porcine collagen (for both groups)

For final inclusion, an additional exclusion criteria will be assessed after randomization:

- Positive to HIV, HBV, HCV, syphilis.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Matrix-Assisted Autologous Chondrocytes Transplantation (MACT); Matrix-Assisted Autologous Chondrocytes Transplantation (MACT, also called third generation of autologous chondrocyte implantation) is based on the use of type I/III collagen membrane as a three-dimensional structural support on which autologous articular chondrocytes are seeded and cultured to form cartilage prior to implantation.	Procedure: MACT; A biopsy of healthy cartilage is taken from a non-weight bearing area of the knee joint during an arthroscopic procedure.; The biopsy is processed in the GMP accredited laboratory to isolate and amplify chondrocytes.; The cells are seeded and cultured on a collagen matrix (Chondro-Gide®, Geistlich Pharma); The membrane is implanted and sutured onto the injured site.; Other Names: Third generation of ACI
Active Comparator: The Augmented Microfracture Technique (AMT); The Augmented Microfracture Technique (AMT, also called Autologous Matrix-Induced Chondrogenesis or AMIC) which is part of a therapeutic continuum, combines a microfracture treatment with the application of a type I/III collagen membrane. The principle is to cover the microfractured area with a resorbable membrane to stabilize the formed blood clot in order to increase the concentration of mesenchymal stem cells and promote their differentiation into a repaired tissue.	Procedure: AMT; This treatment combines the microfracture procedure with the application of a bilayer matrix of porcine type I/III collagen (Chondro-Gide, Geistlich Pharma) and the supplementation of autologous bone.; Other Names: AMIC

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patellofemoral joint-related function and quality-of-life are assessed using the Knee injury and Osteoarthritis Outcome Score (KOOS).	KOOS includes five subscales: symptoms, pain, activities of daily living, function in sport/recreation, and knee-related quality of life. A score in points for each subscale will be calculated, and it ranges from 0 (worst score) to 100 (best score). Self-assessment by the patient	Change from baseline to 3, 6 12, 24, 36, 48 and 60 months post-implantation in the patellofemoral joint.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Femorotibial joint-related function and quality-of-life are assessed using the Knee injury and Osteoarthritis Outcome Score (KOOS).	KOOS includes five subscales: symptoms, pain, activities of daily living, function in sport/recreation, and knee-related quality of life. A score in points for each subscale will be calculated, and it ranges from 0 (worst score) to 100 (best score).Self-assessment by the patient	Change from baseline to 3, 6 12, 24, 36, 48 and 60 months post-implantation in the femorotibial joint.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Self-reported physical pain and function are assessed by International Knee Documentation Committee score (IKDC)	A score will be calculated, and it ranges from 0 (worst score) to 100 (best score).	Change from baseline to 3, 6 12, 24, 36, 48 and 60 months post-implantation in the patellofemoral and femorotibial joints.
Rate of implantation-associated complications: serious adverse events (SAEs) and serious adverse reactions (SARs)	Post-implantation data collection: Types, probability and severity of treatment (inflammation, infection,pain, joint effusion, delamination, transplant rejection, fibrocartilage, incomplete cartilage repair).	Up to 60 months.
The cartilage repair is assesed by Magnetic Resonance Observation of Cartilage Repair	MOCART scoring system is based on MRI analysis. A score in points will be calculated, and it ranges from 0 points (no repair) to 100 points (excellent cartilage defect repair)	Change from baseline to 3, 6 12, 24, 36, 48 and 60 months post-implantation.

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire Vaudois
• Collaborators: Lee Ann LAURENT APPLEGATE; Virginie PHILIPPE
• Investigators: Principal Investigator: Robin MARTIN, MD, CHUV

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): June 1, 2032

Study Registration Dates

• First Submitted: December 7, 2022
• First Submitted That Met QC Criteria: December 14, 2022
• First Posted (Actual): December 15, 2022

Study Record Updates

• Last Update Posted (Actual): March 12, 2026
• Last Update Submitted That Met QC Criteria: March 10, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Cellular therapy; Human articular chondrocytes
• Additional Relevant MeSH Terms: Bone Diseases; Musculoskeletal Diseases; Connective Tissue Diseases; Cartilage Diseases; Skin and Connective Tissue Diseases; Osteochondritis
• Other Study ID Numbers: AMT_MACT_OTR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No